46 completed, 30 recruiting, 10 terminated, 5 unknown. 34 Phase 2, 16 Phase 1, 12 Not applicable, 11 Phase 3, 4 Phase 4.
Follow Glomerulosclerosis, Focal Segmental: new trials by email Literature Review of Glomerulosclerosis, Focal Segmental trials Research Report on Glomerulosclerosis, Focal Segmental
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease Sibeprenlimab - Primary Membranous Nephropathy, Minimal Change Disease | Phase 2 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 20 | 2026-12-15 | 2026-10-06 |
| An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases ManNAc - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | National Human Genome Research Institute (NHGRI) | 30 | 2026-10-27 | 2026-10-30 |
| MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT) Antiphospholipid (aPL)-Positive, Rheumatic Arthritis | Not yet recruiting | Axiom Bioregistry | 5000 | 2026-10-18 | 2026-10-23 | |
| Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases EVER001 - Minimal Change Disease (MCD), IgA Nephropathy (IgAN) | Phase 2 | Recruiting | Everest Medicines (China) Co.,Ltd. | 45 | 2026-05-20 | 2026-08-05 |
| A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) BI 764198, Placebo - Focal Segmental Glomerulosclerosis | Phase 3 | Recruiting | Boehringer Ingelheim | 286 | 2026-02-16 | 2026-10-28 |
| A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) Praliciguat (Part A), Placebo (Part A), Praliciguat (Part B) - Focal Segmental Glomerulosclerosis | Phase 2 | Recruiting | Akebia Therapeutics | 60 | 2025-12-03 | 2026-10-01 |
| Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis ANCA Associated Vasculitis, Extramembranous Glomerulopathy | Recruiting | Assistance Publique - Hôpitaux de Paris | 146 | 2025-11-03 | 2026-06-30 | |
| A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis BAT4406F, Placebos - Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 / Phase 3 | Recruiting | Bio-Thera Solutions | 192 | 2025-10-26 | 2026-04-03 |
| Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis Sparsentan - Proteinuria, Immunoglobulin A (IgA) Nephropathy | Phase 4 | Active not recruiting | Travere Therapeutics, Inc. | 20 | 2025-10-07 | 2026-06-23 |
| SLIT ABS: Study on Patients With Autoimmune Podocytopathy Serum and renal tissue analysis - Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome | Not applicable | Recruiting | Meyer Children's Hospital IRCCS | 50 | 2025-06-10 | 2026-04-08 |
| A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease frexalimab, brivekimig, rilzabrutinib - Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion | Phase 2 | Recruiting | Sanofi | 84 | 2024-12-19 | 2026-10-19 |
| REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE) Prednisone - Nephrotic Syndrome in Children, Nephrotic Syndrome, Minimal Change | Phase 3 | Active not recruiting | The Hospital for Sick Children | 50 | 2024-11-01 | 2026-05-11 |
| Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment IXP - Focal Segmental Glomerulosclerosis (FSGS) | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 36 | 2024-08-02 | 2025-01-20 |
| Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1 Nephrotic Syndrome, Focal Segmental Glomerulosclerosis | Unknown | Assistance Publique - Hôpitaux de Paris | 124 | 2024-06-30 | 2024-06-05 | |
| Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome In-house ELISA, and ELISA kits from "DBA Italy" (Abbexa). - Nephrotic Syndrome | Recruiting | Mario Negri Institute for Pharmacological Research | 100 | 2024-03-19 | 2025-09-04 | |
| AMPK-activation by Metformin in FSGS: AMP-FSGS Metformin + Standard of Care, Placebo + Standard of Care - Focal Segmental Glomerulosclerosis | Phase 1 / Phase 2 | Recruiting | Yale University | 30 | 2023-12-14 | 2026-02-03 |
| A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147 VX-147 - Focal Segmental Glomerulosclerosis (FSGS) | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 21 | 2023-07-19 | 2023-09-13 |
| Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome Rituximab (MABTHERA® or RITUXAN®)., Corticosteroids (CS) - Membranous Nephropathy, Minimal Change Disease (MCD) | Completed | University Hospital, Ioannina | 40 | 2023-06-01 | 2026-07-14 | |
| A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects HS-10390 tablet, Placebo tablet - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 1 | Recruiting | Hansoh BioMedical R&D Company | 84 | 2023-05-23 | 2024-10-09 |
| Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease Baricitinib, Placebo - Chronic Kidney Diseases | Phase 2 | Completed | Duke University | 8 | 2023-04-20 | 2026-04-24 |
Showing 20 of 101. Sign in to see all of them.
Nephrosis, Lipoid (42) · Nephrotic Syndrome (26) · Proteinuria (23) · Glomerulonephritis, IGA (17) · Kidney Diseases (17) · Glomerulonephritis, Membranous (16) · Diabetic Nephropathies (11) · Renal Insufficiency, Chronic (10) · Macular dystrophy, corneal type 1 (9) · Glomerulonephritis (6) · Nephritis, Hereditary (6) · Fibrosis (3) · Nephrosis (3) · Recurrence (3)
Female Urogenital Diseases (101) · Female Urogenital Diseases and Pregnancy Complications (101) · Male Urogenital Diseases (101) · Urogenital Diseases (101) · Nephritis (99) · Urologic Diseases (99) · Glomerulonephritis (95) · Kidney Diseases (84) · Nephrosis (48) · Pathological Conditions, Signs and Symptoms (38) · Immune System Diseases (28) · Autoimmune Diseases (25) · Signs and Symptoms (25) · Urination Disorders (24) · Urological Manifestations (23)
Rituximab (5) · sparsentan (5) · Galactose (4) · Adalimumab (3) · Dexamethasone (3) · Prednisolone (3) · Prednisone (3) · CCX140-B (2) · Irbesartan (2) · Mycophenolic Acid (2) · Plasmapheresis (2) · Tacrolimus (2) · propagermanium (2) · 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-N-(2,2-dimethylprpyl)-3-pyridinecarboxamide (1) · ADX-629 (1)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (11) · Northwell Health (6) · Travere Therapeutics, Inc. (6) · University of Michigan (5) · Goldfinch Bio, Inc. (3) · Vertex Pharmaceuticals Incorporated (3) · Amgen (2) · Assistance Publique - Hôpitaux de Paris (2) · Columbia University (2) · Dimerix Bioscience Pty Ltd (2) · Istanbul University (2) · Kaneka Medical America LLC (2) · Nanjing University School of Medicine (2) · The Hospital for Sick Children (2) · Akebia Therapeutics (1)
United States (64) · United Kingdom (13) · China (12) · France (12) · Italy (12) · Canada (11) · Germany (11) · Spain (9) · Australia (8) · Brazil (6) · Poland (6) · Belgium (5) · Czechia (5) · Mexico (5) · Netherlands (5)
Howard Trachtman, MD (4) · Jeffrey B Kopp, M.D. (4) · Radko Komers, MD, PhD (3) · Debbie Gipson, MD (2) · Matthias Kretzler, MD (2) · Aaron Friedman, MD (1) · Anirban Ganguli, M.D. (1) · Asha Moudgil, MD (1) · Baosong Gui, MD (1) · Cijiang He (1) · Daniel TM Chan, Prof (1) · David Fuller (1) · Deborah Mensch, M.D. (1)
PMID 35224732, PMID 38724717, PMID 40337980, PMID 40938675, PMID 35230699, PMID 37254256, PMID 39513526, PMID 39899371, PMID 19073787, PMID 19932542, PMID 21178977, PMID 21310077, PMID 21734640, PMID 22722778, PMID 22995802, PMID 23615312, PMID 24009220, PMID 26198842, PMID 26577187, PMID 26589142, PMID 26998310, PMID 27445165, PMID 28213606, PMID 30361325, PMID 30732999, PMID 30976899, PMID 32842999, PMID 33412162, PMID 33767059, PMID 34060483, PMID 34169203, PMID 34778952, PMID 34796395, PMID 36657027, PMID 36920755, PMID 37117201, PMID 37675355, PMID 37921461, PMID 38831932, PMID 39015674, PMID 39661388, PMID 39710174, PMID 39808779, PMID 41091558, PMID 41236849, PMID 41433094, PMID 41442197, PMID 41630898, PMID 41774497, PMID 41805697
R01DK131091 (2), R01DK141114 (2), U54DK083912 (2), 2015 (1), 2019 (1), 2023 (1), 2025 (1), 5RC2DK122397 (1), K23DK093556 (1), R01MD016401 (1), R21DK077329 (1), R33DK070341 (1), U01DK063385 (1), U01DK063455 (1), U01DK063490 (1)